BACKGROUND-Hypokalemia and sympathetic activation are commonly associated with electrical storm (ES) in normal and diseased hearts. The mechanisms remain unclear.
Introduction
Electrical storm (ES) describes a clinical condition characterized by multiple spontaneous ventricular fibrillation (SVF) episodes that necessitate repeated defibrillation. While ES usually occurs in patients with serious organic heart diseases, it is not rare in patients with structurally normal hearts and genetic arrhythmias such as Brugada and early repolarization syndromes. It is known that hypokalemia is a common trigger of ES. 1, 2 Bansch et al 3 reported that the recurrence risk of ES was highest in cardiomyopathic patients with hypokalemia and associated conditions such as diarrhea and vomiting. Hypokalemia is also associated with ES in structurally normal hearts and correction of hypokalemia can prevent the recurrent ventricular fibrillation (VF). 4, 5 However, because rapid and safe correction of serum potassium is often difficult, additional drug therapy is often necessary to manage the ES. Sympathetic blockade, while not always effective, is commonly used in the management of ES. 6 This clinical practice is consistent with the observation that sympathetic nerve activity is a direct and immediate trigger of ventricular tachycardia (VT) and ventricular fibrillation (VF). 6 Hypokalemia alone does not enhance VF inducibility in normal dogs. 7 However, sympathetic stimulation with isoproterenol and concomitant hypokalemia can induce VF in a rat model. 8 Massive reactive sympathetic activation 9 and the frequent use of epinephrine during fibrillation-defibrillation episodes 10 may also induce hypokalemia in patients with ES, because beta adrenergic stimulation itself can elicit hypokalemia. 11 We have shown that heart failure in rabbits upregulate a small conductance calcium activated potassium current (I KAS ) and promote late phase 3 early afterdepolarization (EAD) leading to ES. 12, 13 However, as far as we know, there are no animal models of ES in ventricles without chronic structural remodeling.
To test the importance of hypokalemia and sympathetic activation in the development of ES, we aim to develop a model of ES in normal rabbit ventricles in the presence of hypokalemia during isoproterenol infusion. This animal model is then used to test the hypothesis that late phase 3 EAD is important in the recurrence of SVF after defibrillation, similar to that occurs after electrical shocks in normal canine atria. 14 We then tested a third hypothesis that glibenclamide, an I KATP blocker, is effective in preventing ES in this model.
Methods
The details of experimental methods and protocol are available at Online Data Supplement. The isolated rabbit hearts (n=32) were perfused to maintain a perfusion pressure above 70 mmHg throughout the study. Intracellular calcium (Ca i ) and membrane voltage (V m ) were simultaneously mapped using optical mapping techniques as described previously. 12 VF was electrically-induced and allowed to persist for 3 min under maintained coronary perfusion, followed by defibrillation. The set of 3-min VF and 1-min observational period was repeated up to 5 times unless SVF occurred. VF induction and defibrillation were repeated in control and during isoproterenol infusion (0.3 μmol/L) to determine the role of beta-adrenergic stimulation in the action potential duration (APD) shortening after VF episodes (n=5). Thereafter, we tested various levels of [K + ] o (4.5, 2.0, 1.5, and 1.0 mmol/L) during beta-adrenergic stimulation (n=17). In an additional 10 hearts, pharmacological interventions were applied to identify the mechanism of the post-defibrillation APD shortening during beta-adrenergic stimulation at the normal [K + ] o level. APD was measured at 50% (APD 50 ) and 80% (APD 80 ) repolarization. Continuous variables were expressed as mean ± SEM. P≤0.05 was considered statistically significant.
Results

A Model of ES in Normal Ventricles
We successfully developed a model of ES in these normal ventricles. We defined ES as multiple (≥3) consecutive episodes of SVF recurrences after initial successful defibrillation. In control, no SVF was observed with 5 attempts of the induced VF-defibrillation episodes. The ES developed after the 2.7 ± 1.1 th episodes of electricallyinduced VF. In the majority of ES (13/15 hearts, 87%), VTs (cycle length: 345 ± 10 ms) were observed between the SVF episodes. Figure 1A shows a typical example of ES observed under isoproterenol infusion in 1.0 mmol/L [K + ] o . First, a pacing-induced VF was successfully defibrillated. VT followed the successful defibrillation, and then SVF occurred. Despite multiple attempts of defibrillation, all subsequent shocks seemed to fail to defibrillate the SVF on pseudo-ECG. However, optical recordings revealed that each shock actually terminated the SVF successfully, followed by immediate recurrences of SVF. A large difference between APD and Ca i transient duration (Ca i TD) was noted during the ES. The initiation of the SVF was associated with a short-coupled ventricular ectopy ( Figure  1B) . The coupling interval of the ectopic beat that initiated SVF was significantly shorter than that of the ectopic beat not initiating SVF (150 ± 5 ms versus 239 ± 6 ms, P<0.001). There was no apparent QRS or T wave alternans during VT before transition to SVF. Repeated defibrillation (5 ± 2 successful defibrillation, shock intensity: 177 ± 6 V) alone terminated ES in only 2 hearts (14%).
Post-defibrillation VT (Online Figure I ) was observed only during isoproterenol infusion and more frequently with a lower [K + ] o (VT incidence: 17%, 33%, 60%, and 71% at [K + ] o of 4.5, 2.0, 1.5, and 1.0 mmol/L, respectively). Spontaneous Ca i elevations preceded the VT beats, and the VT was effectively suppressed by 10 μmol/L nifedipine but not by ventricular overdrive pacing.
Post-Defibrillation Action Potential Triangulation during Beta-Adrenergic Stimulation
In control, APD was modestly shortened after defibrillation of 3-min electrically-induced VF, which is likely due to dependence of APD on the entire activation history (i.e. shortterm memory effect). However, iteration of VF episodes did not further shorten the postdefibrillation APD, probably because the memory of the APD reached a steady state. This is consistent with our previous results which showed that no marked APD shortening occurred after defibrillation in non-failing hearts. 12, 13 In contrast, the post-defibrillation APD was progressively shortened as VF episodes were repeated during isoproterenol infusion (0.3 μmol/L) even using normal hearts ( Figure 2A ). The magnitude of the post-defibrillation APD shortening at 50% and 80% repolarization were similar in control, while repeated VF episodes during isoproterenol infusion accelerated early repolarization of the postdefibrillation beats, resulting in more shortening of APD 50 than APD 80 and triangulation of the action potential (AP) in some epicardial sites ( Figure 2B and 2C).
Non-Ischemic Activation of ATP-Sensitive Potassium Current
Since the AP triangulation is often observed in an ischemic condition which causes I KATP activation, we tested the effect of an I KATP blocker, glibenclamide (5 μmol/L, n=6). The dominant frequency of pseudo-ECG during VF decreased after administration of glibenclamide (13.7 ± 2.1 Hz to 8.3 ± 0.9 Hz, P<0.005). After defibrillation, glibenclamide prolonged the APD and abolished the post-defibrillation AP triangulation ( Figure 3A ), suggesting activation of I KATP as the mechanism of the APD shortening. However, under maintained coronary perfusion, a significant myocardial ischemia could not be detected after multiple VF episodes by measuring lactate concentrations in coronary sinus effluent (pre-VF: 0.36 ± 0.16 mmol/L versus post-VF: 0.36 ± 0.15 mmol/L, P=0.947). The reversal of the post-defibrillation APD shortening was unlikely to result from a non-specific effect of glibenclamide on other ionic currents such as cystic fibrosis transmembrane regulator chloride current (I CFTR ) which is known to be activated by isoproterenol and blocked by a higher dose of glibenclamide, since a potent inhibitor of I CFTR , CFTR inh -172, (10 μmol/L, n=5) 15 did not affect the post-defibrillation APD ( Figure 3B ). Also, I KAS blocker, apamin (100 nmol/L, n=5) did not prolong the post-defibrillation APD. Thus I KAS plays a role only in failing hearts, 12 but not in the post-defibrillation APD shortening during beta-adrenergic stimulation.
Mechanisms of ES Induced by Hypokalemia and Isoproterenol Infusion
We analyzed simultaneous V m and Ca i optical recordings to identify how hypokalemia promoted the occurrences of SVF and ES. Figure 4 shows the effects of repeated episodes of induced-VF on post-defibrillation APD and Ca i TD. In control (normal [K + ] o , no isoproterenol), multiple VF episodes homogeneously shortened APDs of post-defibrillation beats. Ca i TD was shortened by 10 to 20% corresponding to the APD shortening. As stated above, APD 50 was progressively shortened during isoproterenol infusion with the AP shape being triangulated. In contrast, Ca i TD 50 was not altered, and the difference between Ca i TD 50 and APD 50 (ΔCa i TD 50 -APD 50 ) was increased in the area with the AP triangulation. When [K + ] o was reduced, pre-VF APD was prolonged. However, the APD was shortened again after VF episodes in some sites, thereby enhancing the APD dispersion. In addition, Ca i TD was progressively prolonged after induced-VF episodes by reduced [K + ] o and isoproterenol, leading to a larger ΔCa i TD 50 -APD 50 . Of initial 5 hearts, SVF occurred during isoproterenol infusion at a low [K + ] o after the 2 nd induced-VF in one heart, and after the 5 th induced-VF in 4 hearts. The increased ΔCa i TD 50 -APD 50 and APD dispersion were associated with the recurrent SVF. Figure 5A shows an example of SVF after defibrillation. SVF occurred with a short-coupled ventricular ectopy (filled circle) similar to that seen in ES of human patients. 16 A focal activation arising from the anterior surface of the left ventricle (site (a)) preceded the QRS onset of the first SVF beat by 34 ms, indicating that the SVF originated from this site. The AP triangulation was seen only around the site of origin with increased APD dispersion. Notably, a high V m gradient area secondary to the heterogeneous APD coincided with a functional block line for the initial SVF beat, but not with the site of origin where ΔCa i TD 50 -APD 50 was increased. These findings suggest that Ca i -dependent phase 3 EADs may underlie the mechanism of the first SVF beat, but the increased APD heterogeneity and conduction block facilitated the development of reentry and wavebreak that promoted the development of SVF. In spite of a large V m gradient, there was no evidence of phase 2 reentry. Furthermore, a spatial distribution of dominant frequency during this SVF episode displayed a focal source pattern with the highest dominant frequency site near the site where SVF started, indicating that repetitive focal activations as well as reentry both contributed to the maintenance of the SVF in this case.
We acquired optical data during 59 episodes of SVF. Sixteen episodes of the SVF were initiated by a focal activity arising from the mapped field. In 11 of 16 (69%) episodes, the earliest site for the focal activation had the maximal or submaximal value of ΔCa i TD 50 -APD 50 ( Figure 5B ).
Pharmacological Interventions on ES
We sought a novel therapeutic target for controlling ES by testing the effect of pharmacological interventions. Since I KATP activation is responsible for post-defibrillation APD shortening during sympathetic stimulation, we examined the effect of 5 μmol/L glibenclamide on ES (n=4). Of note, glibenclamide diminished ΔCa i TD 50 -APD 50 (128 ± 15 ms to 53 ± 12 ms, P<0.05) and terminated all the ES episodes ( Figure 6 ). In 7 hearts, we transiently increased the coronary perfusion pressure to determine if a relative ischemia that could not be detected by the lactate assay contributed to the ES. The increase in the perfusion pressure by 59 ± 5 mmHg did not change the APD 50 and never terminated the ES, confirming that I KATP activation cannot be attributed to ischemia in this model. Glibenclamide did not terminate VT except in one heart where VT stopped spontaneously 42 sec after termination of ES with glibenclamide ( Figure 6 ). The remaining VT was suppressed with a selective L-type Ca 2+ channel blocker, nifedipine (10 μmol/L, Online Figure I ).
Because Ca i overload seems essential for the development of SVF, we also tested the effect of nifedipine (10 μmol/L, n=8) on ES. When nifedipine was given before VF induction (pretreatment group, n=3), VT and SVF were prevented even under isoproterenol infusion at 1.0 mmol/L [K + ] o . When pre-treated with nifedipine, APD 50 was still shortened in some sites after VF episodes (-57 ± 9% of the pre-VF values after 5 th VF episode), but concomitant shortening of Ca i TD kept ΔCa i TD 50 -APD 50 small (11 ± 4 ms, Figure 7A ). In contrast, responses to nifedipine varied when nifedipine was administered after ES developed (posttreatment group, n=5). Nifedipine suppressed VT/SVF in one heart that had a long period of VT prior to SVF recurrence ( Figure 7B) . The maximal ΔCa i TD 50 -APD 50 was reduced as a result of shortened Ca i TD by nifedipine (124 ms to 32 ms). The other 4 hearts showed immediate recurrences of SVF before nifedipine treatment (upper panel in Figure 7C ). Nifedipine was not effective in 2 of 4 hearts (ΔCa i TD 50 -APD 50 : 101 ± 5 ms to 95 ± 11 ms, P=0.50). In the remaining 2 hearts, nifedipine inhibited post-defibrillation VT, which prolonged the interval from defibrillation to SVF recurrence. In this case, repeated defibrillation finally terminated the ES (lower panel in Figure 7C ). The suppression of postdefibrillation VT allowed Ca i overload to be more alleviated during the slower escape rhythm, which is the likely mechanism underlying termination of ES. Remarkably, glibenclamide terminated the ES resistant to nifedipine treatment (n=2, Online Figure II) .
APD shortening was a critical component for ES. Therefore, we tested the effect of I Kr blockade with E-4031 (1 μmol/L, n=4), because most of class I and III antiarrhythmic drugs used in the clinical practice prolong APD mainly by blocking I Kr . Contrary to our expectation, E-4031 failed to prolong APD 50 and to terminate the ES (Figure 8 ). E-4031 did not change the maximal ΔCa i TD 50 -APD 50 . E-4031 also failed to suppress VT between SVF episodes. However, rescue dosage of glibenclamide (5 μmol/L) abolished the SVF in all hearts refractory to I Kr blockade.
Discussion
Mechanisms of SVF in Normal Hearts with Hypokalemia and Beta-Adrenergic Stimulation
Because beta-adrenergic stimulation can by itself induce hypokalemia, 11, 17 it is difficult to test the influence of hypokalemia on isoproterenol proarrhythmia in vivo. Langendorff perfusion allowed us to control the potassium levels in the perfusate. With this method, we showed that isoproterenol infusion and concomitant hypokalemia could cause ES in normal rabbit ventricles. During beta-adrenergic stimulation, prolonged VF episodes increased APD dispersion after defibrillation and elicited short-coupled ectopic beats, both of which contributed to SVF. Although the SVF arose from the site where APD was shortened, the APD shortening alone did not cause the SVF. Hypokalemia enhances calcium entry into cardiomyocytes during VF by suppressing sodium-potassium ATPase activity and consequent reverse mode of sodium-calcium exchanger. 18 The Ca i overload resulted in prolongation of Ca i TD, which was necessary for the development of SVF. One may assume that heterogeneous APD shortening cause phase 2 reentry, 19 but there was no evidence of phase 2 reentry in our model. Rather, APD dispersion was related to the formation of unidirectional conduction block ( Figure 5 ). Although a positive V m slope representing the late phase 3 EAD did not always precede the upstroke of triggered activities, the maximal ΔCa i TD 50 -APD 50 predicted the origin for the first SVF beat better than the minimal APD 50 ( Figure 5B ). This strongly supports late phase 3 EAD as the underlying mechanism in which persistence of elevated Ca i with accelerated repolarization promotes inward sodium-calcium exchanger currents. In our experimental setting, optical signal from one pixel reflects activities of hundreds of cardiomyocytes, which may obscure the deflection of late phase 3 EAD in some cases by an averaging effect.
Role of Beta-Adrenergic Stimulation in I KATP Activation
With beta-adrenergic stimulation, APD 50 was more shortened than APD 80 after VF episodes, resulting in AP triangulation. The AP triangulation disappeared with 5 μmol/L glibenclamide, which mainly blocks I KATP at this concentration. Glibenclamide also blocks I CFTR and I Kr at higher concentrations. 20 Because we observed no effects of I CFTR or I Kr blockade on the shortened APD, we excluded major contribution of these ionic currents to the effects of glibenclamide. Therefore, we conclude that I KATP activation is responsible for the AP triangulation. A high metabolic demand with rapid activation during VF under betaadrenergic stimulation might reduce intracellular ATP and activate the I KATP in spite of a negligible lactate production. K ATP channel was thought to open only when exposed to severe metabolic stress such as ischemia, since a relatively low level of intracellular ATP can inhibit the activation of I KATP in cell-free, inside-out patch-clamp studies. 21 However, ATP sensitivity of K ATP channel is lower in intact cells than that of excised inside-out patches because of the presence of intracellular cofactors including ADP, G-protein, H + , extracellular adenosine, 22 and membrane phospholipid. 23 Also, beta-adrenergic-induced cAMP-dependent phosphorylation of channel proteins activates K ATP channel. 24 Recent evidence from mice lacking Kir6.2 that encodes pore-forming subunit of cardiac K ATP channel demonstrated that isoproterenol-induced APD shortening observed in wild-type mice was absent in Kir6.2-knockout mice, indicating that stress by beta-adrenergic stimulation alone can activate I KATP . 25 Furthermore, prolonged rapid ventricular pacing (30 min) was reported to induce non-ischemic activation of I KATP . 26 Taken together, rapid activations during VF under beta-adrenergic stimulation would activate I KATP even in the absence of ischemia. Although VF in in-vivo hearts is inevitably followed by myocardial ischemia that activates I KATP , our results uncovered physiological impacts of sympathetic activation during prolonged VF per se. Insufficient coronary perfusion during cardiopulmonary resuscitation would further promote I KATP activation and Ca i overload, which might shorten the VF duration necessary for the development of recurrent VF. It is true that APD shortening by I KATP activation protects cardiomyocytes by limiting calcium entry, especially during severe metabolic stress. 25 However, our results indicate that excessive APD shortening due to I KATP activation can be critically arrhythmogenic and exacerbates Ca i overload by facilitating VF sustenance. A recent experimental study using cardiomyopathic human hearts also has shown that I KATP blockade has an antiarrhythmic effect on VF even in the presence of myocardial ischemia. 27 
Intervening VTs in ES
Although SVF recurred during post-defibrillation VT in a majority of ES episodes, SVF also occurred in the absence of VT (i.e. during escape rhythm), indicating that VT is not prerequisite for SVF recurrence. It follows that degeneration of VT into VF 28 is an unlikely mechanism of SVF in this model. We found that a late phase 3 EAD is responsible for SVF, while a delayed afterdepolarization was a likely mechanism of the post-defibrillation VT since spontaneous Ca i elevations occurred before the VT beats (Online Figure 1) . Ca i overload is essential for both SVF and post-defibrillation VT; however, APD shortening with I KATP activation is also required for the development of SVF. Recovery from the APD shortening is time-dependent and influenced by the activation cycle length during the postdefibrillation period (Online Figure III) . A higher heart rate during VT seems to promote SVF occurrence by preventing sufficient recovery of APD shortening and Ca i overload. Suppression of VT with nifedipine both reduced the heart rate and reduced Ca 2+ entry into the cells, allowing the heart to better recover from Ca i overload and the APD shortening during the post-defibrillation periods, and terminated ES as long as ΔCa i TD 50 -APD 50 sufficiently decreased.
Clinical Implications
Even if patients have normokalemia at baseline, a high sympathetic tone during ES may cause hypokalemia through beta 2 adrenoreceptor stimulation. 11 It is imperative to maintain a high serum potassium level to prevent ES especially when catecholamine is administered. If a quick restoration of serum potassium level is difficult, I KATP inhibition may be useful in managing this life-threatening condition. Amiodarone, the first-line therapy for ES 1 and shock-resistant VF 29 may in part achieve its antiarrhythmic effects by inhibiting sarcolemmal I KATP 30 in addition to its beta-blocking effect.
Conclusion
Despite maintained tissue perfusion, prolonged episodes of VF under beta-adrenergic activation and hypokalemia could cause heterogeneous APD abbreviation due to nonischemic I KATP activation and Ca i TD prolongation, leading to late phase 3 EAD, triggered activity and SVF. Importantly, once the heart develops recurrent VF, DC shocks alone may not be sufficient to restore normal rhythm. Rapid correction of hypokalemia and I KATP inhibition would be useful in controlling ES.
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